Source comparison
IGF-1 LR3 vs HGH: Research Application Comparison
Half-Life 20–30 hours 3–4 hours IGF-1 LR3 allows less frequent dosing; HGH requires daily administration Mechanism Direct IGF-1 receptor agonist Stimulates hepatic IGF-1 synthesis via GH receptor activation IGF-1 LR3 bypasses somatotropic axis; HGH depends on
This comparison does not assign a generated winner or score.
- Half-Life
- 20–30 hours
- 3–4 hours
- IGF-1 LR3 allows less frequent dosing; HGH requires daily administration
- Mechanism
- Direct IGF-1 receptor agonist
- Stimulates hepatic IGF-1 synthesis via GH receptor activation
- IGF-1 LR3 bypasses somatotropic axis; HGH depends on liver function
- IGFBP Binding
- <10% affinity vs native IGF-1
- Endogenous IGF-1 produced binds IGFBPs normally
- IGF-1 LR3 remains unbound and bioavailable longer
- Tissue Localization
- Initial concentration at injection site
- Systemic distribution via hepatic IGF-1 release
- IGF-1 LR3 shows localized effects before systemic spread
- Feedback Suppression
- Suppresses GH via hypothalamic IGF-1 receptors
- Suppresses GH via elevated IGF-1 and direct negative feedback
- Both suppress endogenous GH production through different pathways
- Professional Assessment
- IGF-1 LR3 suits protocols requiring extended bioavailability and reduced binding protein interference. HGH suits studies examining physiological GH-IGF-1 axis dynamics. Neither replicates endogenous pulsatile GH secretion.